ALDX — Aldeyra Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1341235 ·
Last close
$1.54
Market Cap
$92.89M
52W High
$2.53
52W Low
$1.48
ADV30
1,758,497
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -3,546,918 | -3,452,619 | 66,483,081 | 65,002,305 | 24,326,289 |
| Dec 2025 | 0 | — | -6,667,883 | -6,461,507 | 72,059,317 | 70,041,254 | 27,808,927 |
| Sep 2025 | 0 | — | -8,001,132 | -7,688,341 | 77,801,012 | 59,340,599 | 28,556,469 |
| Jun 2025 | 0 | — | -10,168,732 | -9,767,312 | 84,962,888 | 41,241,269 | 29,674,746 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-33,345,682
Investing CF
$47,736,288
Financing CF
$1,123,556
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.71
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-483,957,253
Inventory
—
Receivables
$755,545
ST Investments
$0
EBIT TTM
$-31,941,352
Pretax Income TTM
$-33,846,661
Interest Exp TTM
$1,905,309
Analysts
5
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -35,265,206 | -33,846,661 | 72,059,317 | 27,808,927 | — | -33,345,682 |
| Dec 2024 | 0 | -60,117,032 | -55,851,444 | 104,606,694 | 33,601,823 | — | -43,208,747 |
| Dec 2023 | 0 | -42,794,083 | -37,542,510 | 148,326,911 | 28,531,881 | — | -30,326,128 |
| Dec 2022 | 0 | -62,679,987 | -62,024,636 | 181,291,657 | 30,283,628 | — | -56,637,187 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.23
Max Pain — expiry 2026-09-18
max pain strike: $1.00 · spot: $1.54 · call oi: 5,606 · put oi: 231
Expected Move to 2026-09-18:
±$0.75
(48.70%) —
implied range
$0.79 –
$2.29
· ATM straddle on $2.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HRTX | HERON THERAPEUTICS, INC. /DE/ | $94.64M | $0.50 | — |
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | $90.50M | $3.49 | — |
| VRCA | Verrica Pharmaceuticals Inc. | $89.67M | $5.22 | — |
| ONCY | ONCOLYTICS BIOTECH INC | $89.52M | $0.75 | — |
| ZOMDF | Zomedica Corp. | $88.20M | $0.09 | — |
News headlines (Yahoo Finance, 1h cache)
Levicept Appoints Darlene Deptula-Hicks as CFO
2026-07-07 08:00 · Yahoo
CEO, President & Director of Aldeyra Therapeutics Picks Up 18% More Stock
2026-06-10 10:51 · Yahoo
Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment
2026-06-05 01:02 · Yahoo
3 Promising Penny Stocks With Market Caps Reaching $300M
2026-06-04 18:07 · Yahoo
Upstart Holdings Leads These 3 Stocks Estimated To Be Trading Below Fair Value
2026-05-15 17:38 · Yahoo
3 Stocks That May Be Undervalued According To Analysts In May 2026
2026-05-15 11:37 · Yahoo
Pleasing Signs As A Number Of Insiders Buy Aldeyra Therapeutics Stock
2026-05-05 10:55 · Yahoo
Extreme Networks And 2 Additional Stocks Estimated To Be Trading Below Their Fair Value
2026-05-01 17:38 · Yahoo
Discover 3 Stocks That Might Be Trading Below Estimated Value
2026-05-01 11:38 · Yahoo
3 Stocks Estimated To Be Trading Below Intrinsic Value By Up To 35.4%
2026-04-29 17:38 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.